Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: A preliminary case-control study

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6663-6667

  Lumachi, Franco ^a   Lo Re, Giovanni ^b   Tozzoli, Renato ^b   D'Aurizio, Federica ^b   Facomer, Flavio ^b   Chiara, Giordano B ^b   Basso, Stefano M M ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

CA 19 9; CEA; Cholangiocarcinoma; CYFRA 21 1; Diagnosis; MMP7; Serum tumor marker

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; MATRILYSIN; ANTIGEN CYFRA21.1; MMP7 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; BILE DUCT NEOPLASMS; BLOOD; CHOLANGIOCARCINOMA; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

AGED; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-19; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84916217921     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Thuluvath PJ, Rai R, Venbrux AC and Yeo CJ: Cholangiocarcinoma. A review. Gastroenterologist 5: 306-315, 1997.
2. Blechacz BR and Gores GJ: Cholangiocarcinoma. Clin Liver Dis 12: 131-150, 2008.
3. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick RD: Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 245: 755-762, 2007.
4. Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ and Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol 107: 1256-1262, 2012.
5. Qin XL, Wang ZR, Shi JS, Lu M, Wang L and He QR: Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA. World J Gastroenterol 10: 427-432, 2004.
6. Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321, 2008.
7. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S and Kubo S: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15: 583-589, 2008.
8. Leelawat K, Sakchinabut S, Narong S and Wannaprasert J: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: Evaluation of diagnostic accuracy. BMC Gastroenterol 9: 30, 2009.
9. Lumachi F, Santeufemia DA, Del Conte A, Mazza F, Tozzoli R, Chiara GB and Basso SM: Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33: 2593-1596, 2013.
10. Lumachi F, Marino F, Orlando R, Chiara GB and Basso SM: Simultaneous multianalyte immunoassay measurement of five serum tumor markers in detection of colorectal cancer. Anticancer Res 32: 985-988, 2012.
11. Patel AH, Harnois DM, Klee GG, LaRusso NF and Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95: 204-207, 2000.
12. Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145: 1215-1229, 2013.
13. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60: 1268-1289, 2014.
14. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF and Pawlik TM: Intrahepatic cholangiocarcinoma: Management options and emerging therapies. J Am Coll Surg 217: 736-750, 2013.
15. Soares KC, Kamel I, Cosgrove DP, Herman JM and Pawlik TM: Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr 3: 18-34, 2014.
16. Kim HJ, Lee KT, Kim SH, Lee JK, Lim JH, Paik SW and Rhee JC: Differential diagnosis of intrahepatic bile duct dilatation without demonstrable mass on ultrasonography or CT: Benign versus malignancy. J Gastroenterol Hepatol 18: 1287-1292, 2003.
17. Blechacz B, Komuta M, Roskams T and Gores GJ: Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8: 512-522, 2011.
18. Halling KC and Kipp BR: Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 38: 1137-1144, 2007.
19. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M and Gruenberger T: Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15: 2787-2794, 2008.
20. Uchiyama K, Yamamoto M, Yamaue H, Ariizumi S, Aoki T, Kokudo N, Ebata T, Nagino M, Ohtsuka M, Miyazaki M, Tanaka E, Kondo S, Uenishi T, Kubo S, Yoshida H, Unno M, Imura S, Shimada M, Ueno M and Takada T: Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma. A multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 18: 443-452, 2011.
21. Tao LY, Cai L, He XD, Liu W and Qu Q: Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg 76: 1210-1213, 2010.
22. Morris-Stiff G, Teli M, Jardine N and Puntis MC: CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreatic Dis Intl 8: 620-626, 2009.
23. Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y and Kuriyama S: CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol 21: 441-445, 2002.
24. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T and Nishiguchi S: Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 88: 1894-1899, 2003.
25. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, Nishiguchi S and Kubo S: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15: 583-589, 2008.
26. Yang X, Liu Y, Yang Y and Li B: Update meta-analysis on MMP-7-181A>G polymorphism and cancer risk: Evidence from 25 studies. Gene 521: 252-258, 2013.
27. Itatsu K, Zen Y, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, Sato Y, Harada K, Sasaki M, Sasaki M, Sakamoto H, Nagino M, Nimura Y, Ohta T and Nakanuma Y: Expression of matrix metalloproteinase-7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol 39: 710-719, 2008.
28. Leelawat K, Narong S, Wannaprasert J and Ratanashuek T: Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol 16: 4697-4703, 2010.
29. Leelawat K, Sakchinabut S, Narong S and Wannaprasert J: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 9: 30, 2009.
30. G. Schulze: The tumor marker tumor M2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4961-4964, 2000.
31. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G and Berretta M: Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 34: 219-228, 2013.